Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort

By sjmartinez • January 8, 2024

Rader F, Oręziak A, Choudhury L, Saberi S, Fermin D, Wheeler MT, Abraham TP, Garcia-Pavia P, Zwas DR, Masri A, Owens A, Hegde SM, Seidler T, Fox S, Balaratnam G, Sehnert AJ, Olivotto I. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort. JACC Heart Fail. 2024 Jan;12(1):164-177. doi: 10.1016/j.jchf.2023.09.028. PMID: 38176782.

Tags: Cardiology/Epi, Cedars Sinai DoM, efficacy, Long-term outcomes, LVOT gradient, NT-proBNP, NYHA functional class, Publications, safety

Related Posts

Race- and Ethnicity-Specific Hospital Arrival and Emergency Medicine Service Activation Times by US State for Ischemic Stroke

Man S, Sun JL, Alhanti B, Mac Grory B, Smith EE, Schwamm LH, Bhatt DL, Saver JL, Xian Y, Uchino K, Fonarow GC. Race- and[...]

Minimally Invasive Surgery Versus Open Craniotomy With Clot Evacuation After Intracerebral Hemorrhage

Murthy SB, Zhang C, Garton ALA, Mac Grory B, Shah S, Fonarow GC, Schwamm LH, Bhatt DL, Smith EE, Falcone GJ, Payabvash S, Ziai WC,[...]

Large-bore mechanical thrombectomy vs standard of care for acute high-risk pulmonary embolism: rationale and design of the PERSEVERE randomized controlled trial

Chopard R, Hobohm L, Barco S, Bangalore S, Giri J, Mahfoud F, Moriarty J, Rosenkranz S, Sharp A, Thiele H, Toma C, Tapson VF, Markovitz[...]